Cargando…
The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome
Type 2 diabetes is traditionally diagnosed by the use of an oral glucose tolerance test and/or HbA1c, both of which require serum collection. Various biomarkers, which are measurable biological substances that provide clinical insight on disease state, have also been effective in the early identific...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553598/ https://www.ncbi.nlm.nih.gov/pubmed/33116710 http://dx.doi.org/10.2147/DMSO.S265879 |
_version_ | 1783593636378705920 |
---|---|
author | Desai, Priya Donovan, Lorin Janowitz, Elizabeth Kim, Joon Young |
author_facet | Desai, Priya Donovan, Lorin Janowitz, Elizabeth Kim, Joon Young |
author_sort | Desai, Priya |
collection | PubMed |
description | Type 2 diabetes is traditionally diagnosed by the use of an oral glucose tolerance test and/or HbA1c, both of which require serum collection. Various biomarkers, which are measurable biological substances that provide clinical insight on disease state, have also been effective in the early identification and risk prediction of inflammatory diseases. Measuring biomarker concentrations has traditionally been obtained through serum collection as well. However, numerous biomarkers are detectable in saliva. Salivary analysis has more recently been introduced into research as a potential non-invasive, cost-effective diagnostic for the early identification of type 2 diabetes risk in adults and youth. Therefore, the purpose of this review was to compare 6 established inflammatory biomarkers of type 2 diabetes, in serum and saliva, and determine if similar diagnostic effectiveness is seen in saliva. A lack of standardized salivary analysis, processing, and collection accounts for errors and inconsistencies in conclusive data amongst studies. Proposing a national standardization in salivary analysis, coupled with increased data and research on the utility of saliva as a diagnostic, poses the potential for salivary analysis to be used in diagnostic settings. |
format | Online Article Text |
id | pubmed-7553598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75535982020-10-27 The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome Desai, Priya Donovan, Lorin Janowitz, Elizabeth Kim, Joon Young Diabetes Metab Syndr Obes Review Type 2 diabetes is traditionally diagnosed by the use of an oral glucose tolerance test and/or HbA1c, both of which require serum collection. Various biomarkers, which are measurable biological substances that provide clinical insight on disease state, have also been effective in the early identification and risk prediction of inflammatory diseases. Measuring biomarker concentrations has traditionally been obtained through serum collection as well. However, numerous biomarkers are detectable in saliva. Salivary analysis has more recently been introduced into research as a potential non-invasive, cost-effective diagnostic for the early identification of type 2 diabetes risk in adults and youth. Therefore, the purpose of this review was to compare 6 established inflammatory biomarkers of type 2 diabetes, in serum and saliva, and determine if similar diagnostic effectiveness is seen in saliva. A lack of standardized salivary analysis, processing, and collection accounts for errors and inconsistencies in conclusive data amongst studies. Proposing a national standardization in salivary analysis, coupled with increased data and research on the utility of saliva as a diagnostic, poses the potential for salivary analysis to be used in diagnostic settings. Dove 2020-10-09 /pmc/articles/PMC7553598/ /pubmed/33116710 http://dx.doi.org/10.2147/DMSO.S265879 Text en © 2020 Desai et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Desai, Priya Donovan, Lorin Janowitz, Elizabeth Kim, Joon Young The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome |
title | The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome |
title_full | The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome |
title_fullStr | The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome |
title_full_unstemmed | The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome |
title_short | The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome |
title_sort | clinical utility of salivary biomarkers in the identification of type 2 diabetes risk and metabolic syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553598/ https://www.ncbi.nlm.nih.gov/pubmed/33116710 http://dx.doi.org/10.2147/DMSO.S265879 |
work_keys_str_mv | AT desaipriya theclinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome AT donovanlorin theclinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome AT janowitzelizabeth theclinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome AT kimjoonyoung theclinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome AT desaipriya clinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome AT donovanlorin clinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome AT janowitzelizabeth clinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome AT kimjoonyoung clinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome |